ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Clinical manifestations and diagnosis of Legionella infection

Clinical manifestations and diagnosis of Legionella infection
Literature review current through: May 2024.
This topic last updated: Oct 17, 2022.

INTRODUCTION — Pneumonia is the most commonly described manifestation of Legionella infection and is termed Legionnaires' disease. Legionella can also cause a self-limiting acute febrile illness, termed Pontiac fever. Rarely, Legionella causes extrapulmonary infections such as cellulitis, abscesses, endocarditis, or meningitis.

The clinical manifestations and diagnosis of Legionella infection will be reviewed here. The epidemiology, pathogenesis, treatment, and prevention are discussed separately. (See "Microbiology, epidemiology, and pathogenesis of Legionella infection" and "Treatment and prevention of Legionella infection".)

LEGIONNAIRES' DISEASE (LEGIONELLA PNEUMONIA)

Clinical features — Pneumonia caused by Legionella is clinically and radiographically similar to other forms of pneumonia. Predominant symptoms include fever, cough, and shortness of breath [1-10]. Symptoms typically arise 2 to 10 days after exposure to contaminated water or soil. Fever and fatigue often precede the onset of cough. Rales and/or other signs of consolidation can be present on physical examination. Sputum may be difficult to obtain. Radiographic findings are varied and nonspecific; however, the most common findings are patchy unilobar infiltrates, which can progress to consolidations [11-13].

Although no clinical features reliably distinguish Legionnaires' disease from other types of pneumonia, certain features may raise the index of suspicion [1-6,10,14-17]. These include:

Gastrointestinal symptoms such as nausea, vomiting, and diarrhea

Hyponatremia

Elevated hepatic transaminases

C-reactive protein levels >100 mg/L

Failure to respond to treatment for pneumonia with beta-lactam monotherapy

Scoring systems combining these clinical and laboratory features have been developed, but none have been validated or proven to have adequate predictive value for diagnosis. A scoring system, developed from a large cohort of cases in the United States using clinical parameters only that could be added to electronic health records and may alert clinicians to consider testing [8,15,17-19].

Legionnaires' disease ranges from mild to severe. In a case series of 214 hospitalized patients with Legionnaires' disease, 47 percent had moderate/severe pneumonia (Pneumonia Severity Index IV to V) and 18 percent required intensive care unit (ICU) admission [20]. In other case series, ICU admission was required in 44 percent. Mortality, even in tertiary care centers, ranges from about 1 to 10 percent [4,20,21]. Mortality after admission to ICU may be over 30 percent with some patients requiring extracorporeal membrane oxygenation [22]. Local complications are uncommon but include empyema and lung abscess. Extrapulmonary complications are rare. (See 'Extrapulmonary Legionella disease' below.)

Clinical features of Legionnaires' disease do not appear to vary with the infecting species or serotypes. In a case series evaluating over 100 patients with Legionnaires' disease, signs and symptoms of Legionella longbeachae pneumonia were largely similar to those of Legionella pneumophila pneumonia [4]. Key differences between these species are epidemiologic. L. pneumophila is found worldwide and typically acquired from contaminated water sources in late summer and early fall. By contrast, L. longbeachae is primarily acquired from soil in late spring and early summer and may have a more restricted geographic distribution (eg, most often reported in Australia and New Zealand). (See "Microbiology, epidemiology, and pathogenesis of Legionella infection", section on 'Epidemiology'.)

Diagnosis

When to suspect Legionella — Legionella infection should be considered in any patient presenting with pneumonia. While the majority of Legionella infections occur sporadically in patients with community-acquired pneumonia (CAP), infection can also be acquired in health care settings.

The index of suspicion for Legionella infection should be particularly high during known outbreaks, which are often associated with contamination of water supplies in large facilities such as hospitals, hotels, or apartment buildings. Other epidemiologic factors that should heighten suspicion for Legionella infection include season, known or potential exposure to a contaminated water source (eg, hot tubs, birthing pools, fountains), travel, and exposure to soil or potting mix in areas where the incidence of L. longbeachae is high. (See "Microbiology, epidemiology, and pathogenesis of Legionella infection", section on 'Geographic variation'.)

Patient risk factors include older age, smoking, and chronic lung, cardiovascular, or renal disease [23-26]. Immunocompromise, particularly impaired cell-mediated immunity, increases both the likelihood of infection and poorer outcome [27-29]. Failure to respond to beta-lactam monotherapy in a patient with pneumonia should also raise suspicion for Legionella infection. Concern may also be raised when the course of a viral infection follows an unexpected course. Fatal cases of coinfection with severe acute respiratory syndrome coronavirus 2 have been reported but these are rare and the association is unclear [30]. (See "Microbiology, epidemiology, and pathogenesis of Legionella infection", section on 'Risk factors'.)

Although certain clinical features (eg, altered mental status, gastrointestinal symptoms, and hyponatremia) might raise suspicion for Legionella infection, no individual symptom or sign or combination is pathognomic. Laboratory testing is necessary for diagnosis.

Whom to test — Because early diagnosis and administration of appropriate antimicrobial therapy is associated with improved outcomes in patients with Legionnaires' disease [31,32], we take an inclusive approach to diagnosis and generally test the following patients:

All patients with moderate to severe CAP or patients with CAP who require hospitalization

Any patient with CAP or nosocomial pneumonia who has a known or possible exposure to Legionella (eg, during an outbreak)

Immunocompromised patients (who are at higher risk for Legionella infection and severe disease)

Our approach is largely consistent with recommendations from the Infectious Diseases Society of America (IDSA), the American Thoracic Society (ATS), the British Thoracic Society (BTS), and the National Institute for Health and Care Excellence (NICE) [33-35]. Each organization recommends testing for Legionella infection in all patients with severe CAP or those who require hospitalization. In addition, IDSA/ATS and BTS guidelines recommend testing for patients with nonsevere CAP who have specific risk factors or epidemiologic exposures [33,35-38].

Approach to testing — The main testing options for Legionella infection include nucleic acid detection (eg, polymerase chain reaction [PCR]), urine antigen tests, and culture (table 1).

  • When testing for Legionella in patients with pneumonia, we prefer to use PCR on a lower respiratory tract sample (eg, sputum or bronchoalveolar lavage specimen) because PCR has high diagnostic accuracy and detects all Legionella species and serogroups.
  • If PCR is not available or if sputum cannot be obtained, urine antigen testing is an acceptable alternative, especially in regions such as the United States where the prevalence of L. pneumophila serogroup 1 is high. The main advantages of the urinary antigen test are its rapid turnaround time and high specificity.

Because the urinary antigen test only detects L. pneumophila serotype 1, we generally send PCR or culture on a lower respiratory tract sample when urine antigen assays are negative and Legionella infection is still suspected. For patients with positive Legionella urinary antigen tests or PCR, we generally also obtain a culture from the lower respiratory tract for epidemiologic purposes (eg, comparison with isolates from other patients or potential sources).

Testing methods

Polymerase chain reaction — PCR is the preferred test for the diagnosis of Legionnaires' disease. PCR can be performed on nearly any sample type and detects all clinically important Legionella species and serotypes. The diagnostic accuracy of PCR appears to be high and exceeds that of culture but is difficult to determine because there is no reliable reference standard [39-43]. The major limitation of PCR is the inability to obtain adequate sputum samples from patients with Legionnaires' disease. For some patients, inducing sputum for testing may enhance diagnostic yield [44]. Testing for upper respiratory samples by PCR is also an alternative; however, the sensitivity is low [44]. Metagenomic next generation sequencing of blood other bodily fluids is under investigation but the sensitivity and specificity is yet to be determined [45].  

Urine Legionella antigen testing — The Legionella urinary antigen test is a commonly used alternative test for Legionnaires' disease. The sensitivity of urine antigen tests ranges from approximately 70 to 80 percent and the specificity approaches 100 percent in patients with Legionnaires' disease caused by L. pneumophila serotype 1 [39,46,47]. Legionella antigens can be detected in urine as early as one day after symptom onset and persist for days to weeks. The turnaround time for the assay is a few hours. Lateral flow devices are simple can be used in most clinical laboratories [48].

The major disadvantage of the assay is that it only detects L. pneumophila serotype 1. While L. pneumophila serotype 1 causes over 80 percent of reported cases of Legionnaires' disease in most regions of the world, L. longbeachae is common in some regions, such as Australia and New Zealand, which limits the utility of the assay [49]. Other urinary antigen systems that detect a broader range of species are under are under investigation [50].

Culture — Culture on special media is considered the gold standard for diagnosis of Legionella infections. Culture can be performed on nearly any sample type and results are typically obtained in approximately three to five days.

For Legionnaires' disease, the sensitivity of sputum cultures is variable with a reported range of <10 to 80 percent [39,46,51]. The specificity of culture nears 100 percent as colonization with Legionella species does not occur. A major limitation of sputum culture is that only about one-half of patients with Legionnaires' disease produce sputum [2-6]. As with other types of pneumonia, induced sputum and bronchoscopic samples appear to have greater diagnostic yield.

Legionella species can be cultured from blood, but the yield is poor and the growth may not activate the alarm on some commercial blood culture machines [52].

The sensitivity of culture also varies with the experience of the microbiology laboratory. Respiratory samples require prompt processing because Legionella bacteria do not survive for prolonged periods in respiratory secretions. In addition, some laboratories reject sputum samples with low polymorphonuclear leukocyte counts [53]. Because lack of purulent sputum is a common finding with Legionnaires' disease, rejection criteria should not be applied when Legionella infection is suspected, and the same applies to PCR testing [54]. Special media, typically buffered charcoal yeast extract (BCYE) agar, is required for culture. BCYE is supplemented with alpha-ketoglutarate and is rich in iron and L-cysteine, both of which are essential for Legionella growth (picture 1).

Antimicrobial susceptibility testing is not routinely performed because there are no standard methods or interpretative criteria [55-58]. The identification of an azithromycin resistance gene (lpeAB genes encoding a macrolide efflux pump) and point mutations in the L. pneumophila 23S rRNA, which mediate intermediate to high levels of macrolide resistance, and a tetracycline destructase gene in L. longbeachae have raised the need for a standardized resistance testing system [58].

Other testing methods — Direct fluorescent antibody (DFA) staining and serology are available but are generally not used in clinical practice. DFA staining has poor sensitivity and cross reacts with other respiratory pathogens. Serology requires collection of acute and convalescent samples spaced four weeks apart, which is clinically impractical. Serology is thus primarily used for retrospective diagnosis in epidemiologic investigations.

OTHER LEGIONELLA INFECTIONS

Pontiac fever — Pontiac fever is an acute, self-limited febrile illness, which can follow exposure to several Legionella species [59]. Symptoms are nonspecific and include fever, headache, chills, myalgias, nausea, vomiting, and diarrhea [60-62]. Symptom onset occurs approximately 4 to 60 hours after exposure (median 36 hours). The duration of illness ranges from approximately one to nine days (median four days) and typically resolves without specific therapy. In contrast with Legionnaires' disease (Legionella pneumonia), signs and symptoms of lower respiratory tract infection are absent.

Clinical suspicion for Pontiac fever is usually based on epidemiologic exposures (eg, current known outbreak or a cluster of cases with similar symptoms, particularly when a common potential source is evident). Because Pontiac fever is typically self-limited, testing is usually not performed unless part of an epidemiologic investigation.

Extrapulmonary Legionella disease — Extrapulmonary Legionella disease is rare and can occur as a complication of Legionella pneumonia or can occur independently. Most cases have been reported in immunocompromised patients [63]. In contrast with Legionnaires' disease and Pontiac fever, many cases of extrapulmonary Legionella disease are caused by Legionella species other than L. pneumophila [64,65].

The range of reported extrapulmonary manifestations is wide and includes cellulitis [66-70], skin and soft tissue abscesses [64,71-73], septic arthritis [74-77], prosthetic joint infection [78], osteomyelitis [79,80], myocarditis [81-85], pericarditis [86-88], native valve and prosthetic valve endocarditis [89-94], peritonitis [95,96], pyelonephritis [97], meningitis [98], brain abscesses [99-101], and surgical site infections [102].

The diagnosis of extrapulmonary disease requires detection of Legionella at the affected site, usually by culture or polymerase chain reaction.

SUMMARY AND RECOMMENDATIONS

Legionnaire's disease (Legionella pneumonia) − Pneumonia is the most commonly described manifestation of Legionella infection and is termed Legionnaires' disease. Legionnaires' disease can be acquired sporadically or during outbreaks, which are often associated with contamination of water supplies in large facilities such as hospitals, hotels, or apartment buildings. (See 'Legionnaires' disease (Legionella pneumonia)' above and "Microbiology, epidemiology, and pathogenesis of Legionella infection", section on 'Epidemiology'.)

Clinically similar to other forms of pneumonia − Pneumonia caused by Legionella is clinically and radiographically similar to other forms of pneumonia. Although there are no signs or symptoms that clearly distinguish Legionnaires' disease from other forms of pneumonia, suggestive clinical features include (see 'Clinical features' above):

Gastrointestinal symptoms such as nausea, vomiting, and diarrhea

Hyponatremia

Elevated hepatic transaminases

C-reactive protein levels >100 mg/L

Failure to respond to treatment for pneumonia with beta-lactam monotherapy

Wide range in severity − Legionnaires' disease ranges from mild to severe. Mortality estimates range from approximately 1 to 10 percent. (See 'Clinical features' above.)

Indications for testing

All hospitalized patients with CAP − Because early diagnosis and administration of appropriate antimicrobial therapy is associated with improved outcomes in patients with Legionnaires' disease, we generally test for Legionella in all patients with moderate to severe community-acquired pneumonia (CAP) or patients with CAP who require hospitalization. (See 'Whom to test' above.)

Patients with pneumonia and known or possible exposure − We also test any patient with CAP or nosocomial pneumonia who has a known or possible exposure to Legionella (eg, during outbreaks) as well as immunocompromised patients with CAP who are at higher risk for infection and/or adverse outcomes. (See 'When to suspect Legionella' above and 'Whom to test' above.)

Test selection

PCR (preferred) − When testing for Legionella in patients with pneumonia, we prefer to use polymerase chain reaction (PCR) on a lower respiratory tract sample (eg, sputum or bronchoalveolar lavage specimen) because PCR has high diagnostic accuracy and detects all Legionella species and serogroups (table 1). (See 'Approach to testing' above and 'Polymerase chain reaction' above.)

Urine antigen testing (alternative) − If PCR is not available or if sputum cannot be obtained, urine antigen testing is an acceptable alternative, especially in regions such as the United States where the prevalence of L. pneumophila serogroup 1 is high. (See 'Approach to testing' above and 'Urine Legionella antigen testing' above.)

Limitations of urine antigen testing − Because the urinary antigen test only detects L. pneumophila serotype 1, we generally send PCR or culture on a lower respiratory tract sample when urine antigen assays are negative and Legionella infection is still suspected. (See 'Approach to testing' above and 'Culture' above.)

Pontiac fever − Pontiac fever is typically diagnosed clinically during outbreaks. Microbiologic confirmation is generally not needed because symptoms are self-limited. (See 'Pontiac fever' above.)

Extrapulmonary infections − Extrapulmonary infections caused by Legionella are rare but reported and include cellulitis, skin abscesses, septic arthritis, myopericarditis, endocarditis, meningitis, and peritonitis. Most extrapulmonary infections occur in immunocompromised patients. Diagnosis requires detection of the organism by culture or PCR from tissue at the affected site. (See 'Extrapulmonary Legionella disease' above.)

ACKNOWLEDGMENTS — The editorial staff at UpToDate acknowledges Victor Yu, MD, Janet Stout, PhD, Nieves Sopena Galindo, MD, and Patricia Priest, MBChB, DPhil, who contributed to earlier versions of this topic review.

  1. Fraser DW, Tsai TR, Orenstein W, et al. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977; 297:1189.
  2. Kirby BD, Snyder KM, Meyer RD, Finegold SM. Legionnaires' disease: report of sixty-five nosocomially acquired cases of review of the literature. Medicine (Baltimore) 1980; 59:188.
  3. Tsai TF, Finn DR, Plikaytis BD, et al. Legionnaires' disease: clinical features of the epidemic in Philadelphia. Ann Intern Med 1979; 90:509.
  4. Isenman HL, Chambers ST, Pithie AD, et al. Legionnaires' disease caused by Legionella longbeachae: Clinical features and outcomes of 107 cases from an endemic area. Respirology 2016; 21:1292.
  5. Sopena N, Sabrià-Leal M, Pedro-Botet ML, et al. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. Chest 1998; 113:1195.
  6. Woodhead MA, Macfarlane JT. Legionnaires' disease: a review of 79 community acquired cases in Nottingham. Thorax 1986; 41:635.
  7. Amodeo MR, Murdoch DR, Pithie AD. Legionnaires' disease caused by Legionella longbeachae and Legionella pneumophila: comparison of clinical features, host-related risk factors, and outcomes. Clin Microbiol Infect 2010; 16:1405.
  8. Fiumefreddo R, Zaborsky R, Haeuptle J, et al. Clinical predictors for Legionella in patients presenting with community-acquired pneumonia to the emergency department. BMC Pulm Med 2009; 9:4.
  9. Roed T, Schønheyder HC, Nielsen H. Predictors of positive or negative legionella urinary antigen test in community-acquired pneumonia. Infect Dis (Lond) 2015; 47:484.
  10. Roig J, Aguilar X, Ruiz J, et al. Comparative study of Legionella pneumophila and other nosocomial-acquired pneumonias. Chest 1991; 99:344.
  11. Poirier R, Rodrigue J, Villeneuve J, Lacasse Y. Early Radiographic and Tomographic Manifestations of Legionnaires' Disease. Can Assoc Radiol J 2017; 68:328.
  12. Tan MJ, Tan JS, Hamor RH, et al. The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest 2000; 117:398.
  13. Gilbert DN. Role of Procalcitonin in the Management of Infected Patients in the Intensive Care Unit. Infect Dis Clin North Am 2017; 31:435.
  14. Lieberman D, Porath A, Schlaeffer F, et al. Legionella species community-acquired pneumonia. A review of 56 hospitalized adult patients. Chest 1996; 109:1243.
  15. Fernández-Sabé N, Rosón B, Carratalà J, et al. Clinical diagnosis of Legionella pneumonia revisited: evaluation of the Community-Based Pneumonia Incidence Study Group scoring system. Clin Infect Dis 2003; 37:483.
  16. Bellew S, Grijalva CG, Williams DJ, et al. Pneumococcal and Legionella Urinary Antigen Tests in Community-acquired Pneumonia: Prospective Evaluation of Indications for Testing. Clin Infect Dis 2019; 68:2026.
  17. Rothberg MB, Imrey PB, Guo N, et al. A risk model to identify Legionella among patients admitted with community-acquired pneumonia: A retrospective cohort study. J Hosp Med 2022; 17:624.
  18. Ito A, Ishida T, Washio Y, et al. Legionella pneumonia due to non-Legionella pneumophila serogroup 1: usefulness of the six-point scoring system. BMC Pulm Med 2017; 17:211.
  19. Miyashita N, Horita N, Higa F, et al. Diagnostic predictors of Legionella pneumonia in Japan. J Infect Chemother 2018; 24:159.
  20. Viasus D, Di Yacovo S, Garcia-Vidal C, et al. Community-acquired Legionella pneumophila pneumonia: a single-center experience with 214 hospitalized sporadic cases over 15 years. Medicine (Baltimore) 2013; 92:51.
  21. Dooling KL, Toews KA, Hicks LA, et al. Active Bacterial Core Surveillance for Legionellosis - United States, 2011-2013. MMWR Morb Mortal Wkly Rep 2015; 64:1190.
  22. Andrea L, Dicpinigaitis PV, Fazzari MJ, Kapoor S. Legionella Pneumonia in the ICU: A Tertiary Care Center Experience Over 10 Years. Crit Care Explor 2021; 3:e0508.
  23. Den Boer JW, Nijhof J, Friesema I. Risk factors for sporadic community-acquired Legionnaires' disease. A 3-year national case-control study. Public Health 2006; 120:566.
  24. Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality. Arch Intern Med 1994; 154:2417.
  25. Straus WL, Plouffe JF, File TM Jr, et al. Risk factors for domestic acquisition of legionnaires disease. Ohio legionnaires Disease Group. Arch Intern Med 1996; 156:1685.
  26. Kenagy E, Priest PC, Cameron CM, et al. Risk Factors for Legionella longbeachae Legionnaires' Disease, New Zealand. Emerg Infect Dis 2017; 23:1148.
  27. Lanternier F, Tubach F, Ravaud P, et al. Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest 2013; 144:990.
  28. Tubach F, Ravaud P, Salmon-Céron D, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 2006; 43:e95.
  29. Sivagnanam S, Podczervinski S, Butler-Wu SM, et al. Legionnaires' disease in transplant recipients: A 15-year retrospective study in a tertiary referral center. Transpl Infect Dis 2017; 19.
  30. Chalker VJ, Adler H, Ball R, et al. Fatal Co-infections with SARS-CoV-2 and Legionella pneumophila, England. Emerg Infect Dis 2021; 27:2950.
  31. Heath CH, Grove DI, Looke DF. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis 1996; 15:286.
  32. Levcovich A, Lazarovitch T, Moran-Gilad J, et al. Complex clinical and microbiological effects on Legionnaires' disease outcone; A retrospective cohort study. BMC Infect Dis 2016; 16:75.
  33. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 Suppl 3:iii1.
  34. National Institute for Health and Care Excellence. Pneumonia in adults: Diagnosis and management. https://www.nice.org.uk/guidance/cg191 (Accessed on December 12, 2017).
  35. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.
  36. Lim WS, Smith DL, Wise MP, et al. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. Thorax 2015; 70:698.
  37. Allgaier J, Lagu T, Haessler S, et al. Risk Factors, Management, and Outcomes of Legionella Pneumonia in a Large, Nationally Representative Sample. Chest 2021; 159:1782.
  38. Pouderoux C, Ginevra C, Descours G, et al. Slowly or Nonresolving Legionnaires' Disease: Case Series and Literature Review. Clin Infect Dis 2020; 70:1933.
  39. Peci A, Winter AL, Gubbay JB. Evaluation and Comparison of Multiple Test Methods, Including Real-time PCR, for Legionella Detection in Clinical Specimens. Front Public Health 2016; 4:175.
  40. Chen DJ, Procop GW, Vogel S, et al. Utility of PCR, Culture, and Antigen Detection Methods for Diagnosis of Legionellosis. J Clin Microbiol 2015; 53:3474.
  41. Cristovam E, Almeida D, Caldeira D, et al. Accuracy of diagnostic tests for Legionnaires' disease: a systematic review. J Med Microbiol 2017; 66:485.
  42. Mentasti M, Fry NK, Afshar B, et al. Application of Legionella pneumophila-specific quantitative real-time PCR combined with direct amplification and sequence-based typing in the diagnosis and epidemiological investigation of Legionnaires' disease. Eur J Clin Microbiol Infect Dis 2012; 31:2017.
  43. Muyldermans A, Descheemaeker P, Boel A, et al. What is the risk of missing legionellosis relying on urinary antigen testing solely? A retrospective Belgian multicenter study. Eur J Clin Microbiol Infect Dis 2020; 39:729.
  44. Maze MJ, Slow S, Cumins AM, et al. Enhanced detection of Legionnaires' disease by PCR testing of induced sputum and throat swabs. Eur Respir J 2014; 43:644.
  45. Wang Y, Dai Y, Lu H, et al. Case Report: Metagenomic Next-Generation Sequencing in Diagnosis of Legionella pneumophila Pneumonia in a Patient After Umbilical Cord Blood Stem Cell Transplantation. Front Med (Lausanne) 2021; 8:643473.
  46. Diederen BM. Legionella spp. and Legionnaires' disease. J Infect 2008; 56:1.
  47. Shimada T, Noguchi Y, Jackson JL, et al. Systematic review and metaanalysis: urinary antigen tests for Legionellosis. Chest 2009; 136:1576.
  48. Wong AYW, Johnsson ATA, Iversen A, et al. Evaluation of Four Lateral Flow Assays for the Detection of Legionella Urinary Antigen. Microorganisms 2021; 9.
  49. Yu VL, Plouffe JF, Pastoris MC, et al. Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis 2002; 186:127.
  50. Ito A, Yamamoto Y, Ishii Y, et al. Evaluation of a novel urinary antigen test kit for diagnosing Legionella pneumonia. Int J Infect Dis 2021; 103:42.
  51. Murdoch DR, Podmore RG, Anderson TP, et al. Impact of routine systematic polymerase chain reaction testing on case finding for Legionnaires' disease: a pre-post comparison study. Clin Infect Dis 2013; 57:1275.
  52. Rihs JD, Yu VL, Zuravleff JJ, et al. Isolation of Legionella pneumophila from blood with the BACTEC system: a prospective study yielding positive results. J Clin Microbiol 1985; 22:422.
  53. Ingram JG, Plouffe JF. Danger of sputum purulence screens in culture of Legionella species. J Clin Microbiol 1994; 32:209.
  54. Shakeshaft MK, Murdoch DR. Microscopic Screening of Sputum Samples Should not be Used when Testing for Legionella Species. Clin Infect Dis 2020; 71:1356.
  55. Massip C, Descours G, Ginevra C, et al. Macrolide resistance in Legionella pneumophila: the role of LpeAB efflux pump. J Antimicrob Chemother 2017; 72:1327.
  56. Shadoud L, Almahmoud I, Jarraud S, et al. Hidden Selection of Bacterial Resistance to Fluoroquinolones In Vivo: The Case of Legionella pneumophila and Humans. EBioMedicine 2015; 2:1179.
  57. Forsberg KJ, Patel S, Wencewicz TA, Dantas G. The Tetracycline Destructases: A Novel Family of Tetracycline-Inactivating Enzymes. Chem Biol 2015; 22:888.
  58. Portal E, Descours G, Ginevra C, et al. Legionella antibiotic susceptibility testing: is it time for international standardization and evidence-based guidance? J Antimicrob Chemother 2021; 76:1113.
  59. Chambers ST, Slow S, Scott-Thomas A, Murdoch DR. Legionellosis Caused by Non-Legionella pneumophila Species, with a Focus on Legionella longbeachae. Microorganisms 2021; 9.
  60. Burnsed LJ, Hicks LA, Smithee LM, et al. A large, travel-associated outbreak of legionellosis among hotel guests: utility of the urine antigen assay in confirming Pontiac fever. Clin Infect Dis 2007; 44:222.
  61. Edelstein PH and Roy CR. Legionnaires' Disease and Pontiac Fever. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8, Bennet JE, Dolin R and Blaser MJ (Eds), Elsevier, Pennsylvania 2015.
  62. Ambrose J, Hampton LM, Fleming-Dutra KE, et al. Large outbreak of Legionnaires' disease and Pontiac fever at a military base. Epidemiol Infect 2014; 142:2336.
  63. Franco-Garcia A, Varughese TA, Lee YJ, et al. Diagnosis of Extrapulmonary Legionellosis in Allogeneic Hematopoietic Cell Transplant Recipients by Direct 16S Ribosomal Ribonucleic Acid Sequencing and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. Open Forum Infect Dis 2017; 4:ofx140.
  64. Qin X, Abe PM, Weissman SJ, Manning SC. Extrapulmonary Legionella micdadei infection in a previously healthy child. Pediatr Infect Dis J 2002; 21:1174.
  65. Muder RR, Yu VL. Infection due to Legionella species other than L. pneumophila. Clin Infect Dis 2002; 35:990.
  66. Han JH, Nguyen JC, Harada S, et al. Relapsing Legionella pneumophila cellulitis: a case report and review of the literature. J Infect Chemother 2010; 16:439.
  67. Kilborn JA, Manz LA, O'Brien M, et al. Necrotizing cellulitis caused by Legionella micdadei. Am J Med 1992; 92:104.
  68. Loridant S, Lagier JC, La Scola B. Identification of Legionella feeleii cellulitis. Emerg Infect Dis 2011; 17:145.
  69. Waldor MK, Wilson B, Swartz M. Cellulitis caused by Legionella pneumophila. Clin Infect Dis 1993; 16:51.
  70. Padrnos LJ, Blair JE, Kusne S, et al. Cutaneous legionellosis: case report and review of the medical literature. Transpl Infect Dis 2014; 16:307.
  71. Gubler JG, Schorr M, Gaia V, et al. Recurrent soft tissue abscesses caused by Legionella cincinnatiensis. J Clin Microbiol 2001; 39:4568.
  72. Barigou M, Cavalie L, Daviller B, et al. Isolation on Chocolate Agar Culture of Legionella pneumophila Isolates from Subcutaneous Abscesses in an Immunocompromised Patient. J Clin Microbiol 2015; 53:3683.
  73. Chitasombat MN, Ratchatanawin N, Visessiri Y. Disseminated extrapulmonary Legionella pneumophila infection presenting with panniculitis: case report and literature review. BMC Infect Dis 2018; 18:467.
  74. Banderet F, Blaich A, Soleman E, et al. Septic arthritis due to Legionella cincinnatiensis: case report and review of the literature. Infection 2017; 45:551.
  75. Thurneysen C, Boggian K. Legionella pneumophila serogroup 1 septic arthritis with probable endocarditis in an immunodeficient patient. J Clin Rheumatol 2014; 20:297.
  76. Just SA, Knudsen JB, Uldum SA, Holt HM. Detection of Legionella bozemanae, a new cause of septic arthritis, by PCR followed by specific culture. J Clin Microbiol 2012; 50:4180.
  77. Flendrie M, Jeurissen M, Franssen M, et al. Septic arthritis caused by Legionella dumoffii in a patient with systemic lupus erythematosus-like disease. J Clin Microbiol 2011; 49:746.
  78. Fernández-Cruz A, Marín M, Castelo L, et al. Legionella micdadei, a new cause of prosthetic joint infection. J Clin Microbiol 2011; 49:3409.
  79. McClelland MR, Vaszar LT, Kagawa FT. Pneumonia and osteomyelitis due to Legionella longbeachae in a woman with systemic lupus erythematosus. Clin Infect Dis 2004; 38:e102.
  80. Sanchez MC, Sebti R, Hassoun P, et al. Osteomyelitis of the patella caused by Legionella anisa. J Clin Microbiol 2013; 51:2791.
  81. Damásio AF, Rodrigues L, Miranda L, et al. Fulminant myocarditis caused by Legionella pneumophila: case report. Rev Port Cardiol 2014; 33:185.e1.
  82. Ishimaru N, Suzuki H, Tokuda Y, Takano T. Severe Legionnaires' disease with pneumonia and biopsy-confirmed myocarditis most likely caused by Legionella pneumophila serogroup 6. Intern Med 2012; 51:3207.
  83. de Lassence A, Matsiota-Bernard P, Valtier B, et al. A case of myocarditis associated with Legionnaires' disease. Clin Infect Dis 1994; 18:120.
  84. Armengol S, Domingo C, Mesalles E. Myocarditis: a rare complication during Legionella infection. Int J Cardiol 1992; 37:418.
  85. Burke PT, Shah R, Thabolingam R, Saba S. Suspected Legionella-induced perimyocarditis in an adult in the absence of pneumonia: a rare clinical entity. Tex Heart Inst J 2009; 36:601.
  86. Schaumann R, Pönisch W, Helbig JH, et al. Pericarditis after allogeneic peripheral blood stem cell transplantation caused by Legionella pneumophila (non-serogroup 1). Infection 2001; 29:51.
  87. Sviri S, Raveh D, Boldur I, et al. Legionella feeleii pneumonia and pericarditis. J Infect 1997; 34:277.
  88. Scerpella EG, Whimbey EE, Champlin RE, Bodey GP. Pericarditis associated with Legionnaires' disease in a bone marrow transplant recipient. Clin Infect Dis 1994; 19:1168.
  89. Fukuta Y, Yildiz-Aktas IZ, William Pasculle A, Veldkamp PJ. Legionella micdadei prosthetic valve endocarditis complicated by brain abscess: case report and review of the literature. Scand J Infect Dis 2012; 44:414.
  90. Leggieri N, Gouriet F, Thuny F, et al. Legionella longbeachae and endocarditis. Emerg Infect Dis 2012; 18:95.
  91. Patel MC, Levi MH, Mahadevi P, et al. L. micdadei PVE successfully treated with levofloxacin/valve replacement: case report and review of the literature. J Infect 2005; 51:e265.
  92. Pearce MM, Theodoropoulos N, Mandel MJ, et al. Legionella cardiaca sp. nov., isolated from a case of native valve endocarditis in a human heart. Int J Syst Evol Microbiol 2012; 62:2946.
  93. Samuel V, Bajwa AA, Cury JD. First case of Legionella pneumophila native valve endocarditis. Int J Infect Dis 2011; 15:e576.
  94. Tompkins LS, Roessler BJ, Redd SC, et al. Legionella prosthetic-valve endocarditis. N Engl J Med 1988; 318:530.
  95. Arnouts PJ, Ramael MR, Ysebaert DK, et al. Legionella pneumophila peritonitis in a kidney transplant patient. Scand J Infect Dis 1991; 23:119.
  96. Dournon E, Bure A, Kemeny JL, et al. Legionella pneumophila peritonitis. Lancet 1982; 1:1363.
  97. Dorman SA, Hardin NJ, Winn WC Jr. Pyelonephritis associated with Legionella pneumophila, serogroup 4. Ann Intern Med 1980; 93:835.
  98. Perpoint T, Jamilloux Y, Descloux E, et al. PCR-confirmed Legionella non-pneumophila meningoencephalitis. Med Mal Infect 2013; 43:32.
  99. Charles M, Johnson E, Macyk-Davey A, et al. Legionella micdadei brain abscess. J Clin Microbiol 2013; 51:701.
  100. Guy SD, Worth LJ, Thursky KA, et al. Legionella pneumophila lung abscess associated with immune suppression. Intern Med J 2011; 41:715.
  101. Andersen BB, Søgaard I. Legionnaires' disease and brain abscess. Neurology 1987; 37:333.
  102. Lowry PW, Blankenship RJ, Gridley W, et al. A cluster of legionella sternal-wound infections due to postoperative topical exposure to contaminated tap water. N Engl J Med 1991; 324:109.
Topic 7035 Version 27.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟